NYSE$MCK
McKesson Corp · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
McKesson reported a 5% increase in total revenues and a decrease of 1% in adjusted earnings per diluted share.
McKesson Corporation reported a 5% increase in total revenues to $70.2 billion for the second quarter of fiscal year 2023. Earnings per diluted share from continuing operations increased to $6.46, while adjusted earnings per diluted share decreased by 1% to $6.06. The company raised its full-year adjusted earnings per diluted share guidance.
- Total revenues increased by 5% to $70.2 billion.
- Earnings per diluted share from continuing operations increased by $4.75 to $6.46.
- Adjusted Earnings per Diluted Share decreased 1% to $6.06.
- Fiscal 2023 Adjusted Earnings per Diluted Share guidance range increased to $24.45 to $24.95.
Headline financials
Revenue & EPS history
McKesson · Revenue · Quarterly
$70.2B
Revenue by segment
McKesson · $3.86B total across 2 segments · Q2 2023
- Medical-Surgical Solutions$2.84B-9.0%73.6%
- Prescription Technology Solutions$1.02B+9.2%26.4%
Forward guidance
McKesson raised fiscal 2023 Adjusted Earnings per Diluted Share guidance to $24.45 to $24.95 from the previous range of $23.95 to $24.65 to reflect operating business performance and increased contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs and COVID-19 tests.
Tailwinds
- U.S. government’s COVID-19 vaccine distribution program: $0.60 to $0.70
- U.S. government’s kitting, storage, and distribution of ancillary supplies program and COVID-19 tests: $1.00 to $1.10
- Fiscal 2023 Adjusted Earnings per Diluted Share guidance indicates 11% to 14% forecasted growth compared to prior year, excluding the impacts of the above items from both fiscal 2023 guidance and fiscal 2022 results.
- McKesson signed an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2027.
- McKesson continues to expand its differentiated oncology and biopharma businesses, further demonstrating meaningful progress against its company priorities.
Headwinds
- Net gains and losses associated with McKesson Ventures’ equity investments: Approximately ($0.15)
- Second-quarter Adjusted Earnings per Diluted Share was $6.06 compared to $6.15 a year ago, a decrease of 1%, driven by prior year net gains from McKesson Ventures' equity investments and lower contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs and COVID-19 tests, partially offset by a lower share count.
- Second-quarter Adjusted Earnings per Diluted Share included pre-tax net losses of approximately $3 million associated with McKesson Ventures' equity investments, compared to pre-tax net gains of approximately $97 million in the second-quarter of fiscal 2022.
- Second-quarter revenues for Medical-Surgical Solutions Segment decreased by 9%, driven by lower sales of COVID-19 tests, partially offset by growth in the primary care business.
- Second-quarter revenues for International Segment decreased by 25%, driven by the divestitures of McKesson's UK and Austrian businesses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.2%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+1.1%
Avg return
30 days after
60%
44 / 73 earnings
Positive
+16.5%
Q3 2026
Best reaction
-21.7%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -3.4% | +2.8% | |
| Q3 2026 | +16.5% | +13.8% | +11.8% | |
| Q2 2026 | +1.5% | +1.4% | -4.2% | |
| Q1 2026 | -5.8% | -6.4% | -2.3% | |
| Q4 2025 | +0.4% | -1.2% | +3.3% | |
| Q3 2025 | -1.2% | +0.6% | +6.1% | |
| Q2 2025 | +15.7% | +17.2% | +14.9% | |
| Q1 2025 | -10.9% | -10.3% | -17.9% | |
| Q4 2024 | +1.9% | +5.0% | +9.9% | |
| Q3 2024 | -2.5% | -2.4% | +4.1% | |
| Q2 2024 | -1.7% | +1.0% | +2.0% | |
| Q1 2024 | +7.4% | +4.2% | +1.8% | |
| Q4 2023 | +6.2% | +6.6% | +5.1% | |
| Q3 2023 | -3.2% | -5.4% | -8.7% | |
| Q2 2023 | +0.1% | +1.9% | -2.5% | |
| Q1 2023 | +0.8% | +3.7% | +8.6% | |
| Q4 2022 | +4.5% | +3.1% | -1.1% | |
| Q3 2022 | +4.1% | +5.2% | +9.7% | |
| Q2 2022 | +5.3% | +6.6% | +3.6% | |
| Q1 2022 | -3.3% | -4.6% | -0.1% | |
| Q4 2021 | +4.5% | +4.7% | +3.1% | |
| Q3 2021 | +1.0% | +1.9% | -4.1% | |
| Q2 2021 | +9.2% | +12.4% | +17.8% | |
| Q1 2021 | +4.6% | +1.2% | +4.1% | |
| Q4 2020 | +0.8% | +3.3% | +8.3% | |
| Q3 2020 | +5.7% | +8.6% | +0.8% | |
| Q2 2020 | -11.0% | -7.9% | -3.2% | |
| Q1 2020 | +4.0% | +1.5% | -3.0% | |
| Q4 2019 | +7.1% | +0.6% | +3.7% | |
| Q3 2019 | +1.9% | +5.4% | -0.4% | |
| Q2 2019 | -2.6% | +2.1% | -0.3% | |
| Q1 2019 | -7.1% | -5.8% | -2.8% | |
| Q4 2018 | -0.7% | -3.8% | +1.4% | |
| Q3 2018 | -5.7% | -9.7% | -11.2% | |
| Q2 2018 | -10.4% | -8.9% | -4.4% | |
| Q1 2018 | -2.3% | -3.1% | -11.3% | |
| Q4 2017 | +7.7% | +11.9% | +12.5% | |
| Q3 2017 | -6.6% | -7.6% | +1.7% | |
| Q2 2017 | -21.7% | -18.5% | -9.8% | |
| Q1 2017 | -1.4% | -2.1% | -6.9% | |
| Q4 2016 | +2.7% | — | — | |
| Q3 2016 | -6.4% | — | — | |
| Q2 2016 | -2.0% | — | — | |
| Q1 2016 | -4.1% | — | — | |
| Q4 2015 | +1.7% | — | — | |
| Q3 2015 | +5.7% | — | — | |
| Q2 2015 | -2.1% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +5.3% | — | — | |
| Q3 2014 | +0.7% | — | — | |
| Q2 2014 | +8.3% | — | — | |
| Q1 2014 | +5.4% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | -2.3% | — | — | |
| Q2 2013 | +3.4% | — | — | |
| Q1 2013 | -1.0% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +3.0% | — | — | |
| Q2 2012 | +6.3% | — | — | |
| Q1 2012 | +0.7% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2011 | +2.3% | — | — | |
| Q2 2011 | +6.0% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q4 2008 | +3.8% | — | — | |
| Q4 2010 | +3.8% | — | — | |
| Q3 2010 | -3.1% | — | — | |
| Q3 2009 | -3.1% | — | — | |
| Q2 2010 | -3.2% | — | — | |
| Q2 2009 | +8.9% | — | — | |
| Q1 2009 | +8.9% | — | — | |
| Q1 2010 | +8.9% | — | — | |
| Q4 2009 | +8.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro